Market News & Trends
Novavax & Catalent Biologics Enter Strategic Partnership
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit recently announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to……..
Designing a CMC Strategy for Accelerated Development of Biotherapeutics
As the pipeline of biologic drugs intended to treat complex disease expands, the typical timeline for drug development seems to be shortening more frequently and with more intensity……..
Innate Pharma Announces Publication of Phase I Clinical Trial Results
Innate Pharma SA recently announced the online publication in The Lancet Oncology of the results from the completed Phase 1 dose-escalation and expansion clinical trial…
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA
Cara Therapeutics, Inc. recently announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic…
Theralase Announces Health Canada Approves Amended Clinical Trial Application
Theralase Technologies Inc. recently announced that Health Canada has issued a No Objection Letter (NOL) for an amended Clinical Trial Application (CTA) for its Phase…
Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement With ChemImage
Predictive Oncology recently announced it has signed a collaborative research agreement with molecular imaging company, ChemImage, to establish the feasibility of coupling genomics to Raman…
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783
Aptinyx Inc. recently announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-783, demonstrating that the product candidate robustly attenuated alcohol-seeking and…
Ziopharm Oncology Completes Enrollment of Phase 1 Combination Trial
Ziopharm Oncology, Inc. recently announced completion of enrollment of the third cohort of a Phase 1 clinical trial evaluating Controlled IL-12 (Ad-RTS-hIL-12 plus veledimex, Ad+V),…
Janssen Announces Collaboration to Expand Data Science Research in Healthcare
Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), recently announced a collaboration with the University of California,…
From ASCO 2019: TILs a Cause for Hope in Melanoma, Cervical & Breast Cancers
As the Spring heat made the light dance around the skin of the largest convention center in America, winners emerged from ASCO last month. One of the most significant announcements (from Iovance Biotherapeutics Inc.) were two first-in-man studies of adoptive T cell therapy (ACT) in patients with melanoma and cervical cancer which had failed to respond to other treatments.
Double Chamber Prefilled Syringes Market Likely to be Driven by Growing Requirement of Highly Efficient Parental Drug Delivery Modes
A new study on Double Chamber Prefilled Syringes, opines global double chamber prefilled syringes market to grow at a CAGR of 9% during the forecast period. Over…
PHASTAR Enters Technology Partnership With Medidata
PHASTAR recently announced today it has entered into a technology partnership with Medidata Solutions, Inc. PHASTAR will deploy several solutions from the Medidata Rave Clinical Cloud, including Rave EDC, Coder, eCOA, and RTSM.
AbbVie Attempts to Secure Long-Term Growth Via Allergan Mega-Merger
Following the news that AbbVie has acquired Allergan for $63 billion, Maura Musciacco, MSc, Senior Director of Neurology & Ophthalmology at GlobalData, a leading data and analytics company, offers her view on this mega-merger.
Oxford BioTherapeutics Announces Receipt of Milestone Payment From Boehringer Ingelheim
Oxford BioTherapeutics Ltd. recently announced that it has received a milestone payment from Boehringer Ingelheim (BI). In addition to OBT’s two clinical stage assets, MEN1309/OBT076…
Dova Pharmaceuticals Announces FDA Approval of Supplemental NDA
Dova Pharmaceuticals, Inc. recently announced the US FDA approved a supplemental New Drug Application (sNDA) that expands the use of DOPTELET (avatrombopag) to include the treatment of thrombocytopenia in adults with…….
Intensity Therapeutics Announces Clinical Collaboration With Merck
Intensity Therapeutics, Inc. recently announced it has entered into an agreement with Merck through a subsidiary to evaluate the combination of Intensity’s lead product candidate…
Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies
The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.
Global DNA Sequencing: Research, Applied & Clinical Markets
The global sequencing market should grow from $10.7 billion in 2018 to $24.4 billion by 2023, with a compound annual growth rate (CAGR) of 18.0% for the period of 2018-2023.
Athenex Announces US FDA Allowance of IND Application
Athenex, Inc. recently announced that the US FDA has allowed the company’s Investigational New Drug (IND) application for the clinical investigation of PT01 (Pegtomarginase) for…
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial, Receives RMAT Designation
Krystal Biotech, Inc. recently announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase1…
